The Antibody Drug Conjugate Summit 2017 covers topics such as:
- Ensure product and process robustness Make more evidence-based decisions
- Increase benefits of ADC- dial in potency, target stratified patient populations and optimize dosing regimens
- How to screen for optimal site of conjugation, select better quality targets and explore new payload mechanisms of action
- Explore alternative opportunities for ADCs by reviewing the potential of using ADCs outside oncology Learn about advances in Protein Modeling and Engineering Breakthroughs
- Characterization of ADCs, Preclinical and Clinical Advances, Translational Considerations
- Linker Design Decisions, Novel Payloads and Linker Technology, Next-Generation Chemistry for Improved Conjugation and Linker Stability
- Engineering ADCs for Developability, Enhanced Specificity and Binding, and Reduced Toxicity
The Antibody Drug Conjugate Summit 2017 brings together senior attendees from:
- Research & Development
- Discovery Chemistry
- Toxicology
- Antibody Discovery
- Protein Engineering
- Biologics
- Biotherapeutics
- Molecular Biology
- Process Sciences
- Oncology Molecules
- Development Analytics and New Technologies
- Biopharmaceutical Development
- Biologics Discovery and Design
- Clinical Assay
As well as:
- Chief Development Officers
- Chief Technology Officers
- Senior Research Officers
- Chief Scientific Officers
